Form 8-K - Current report:
SEC Accession No. 0001213900-22-016733
Filing Date
2022-03-31
Accepted
2022-03-31 16:05:01
Documents
13
Period of Report
2022-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT FILING ea157645-8k_abvc.htm   iXBRL 8-K 25354
2 PRESS RELEASE DATED MARCH 31, 2022 ea157645ex99-1_abvc.htm EX-99.1 103418
  Complete submission text file 0001213900-22-016733.txt   313134

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE abvc-20220331.xsd EX-101.SCH 3048
4 XBRL LABEL FILE abvc-20220331_lab.xml EX-101.LAB 34476
5 XBRL PRESENTATION FILE abvc-20220331_pre.xml EX-101.PRE 22605
7 EXTRACTED XBRL INSTANCE DOCUMENT ea157645-8k_abvc_htm.xml XML 3496
Mailing Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538
Business Address 44370 OLD WARM SPRINGS BLVD. FREMONT CA 94538 510-668-0881
ABVC BIOPHARMA, INC. (Filer) CIK: 0001173313 (see all company filings)

EIN.: 260014658 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40700 | Film No.: 22792381
SIC: 2834 Pharmaceutical Preparations